SAGE Therapeutics (SAGE) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Sage Therapeutics Announces Second Quarter 2020 Financial Results and Highlights Pipeline and Business Progress
August 10, 2020 6:30 AM EDTPipeline progress continues with first patient dosed and ongoing enrollment in multiple clinical trials across the depression and neurology franchises
Durability of response was observed in patients with MDD who responded to a 2-week treatment with zuranolone in MOUNTAIN Study six-month follow-up period
Conference call today at 8:30 a.m. ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating... More
